[HTML][HTML] Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy
DNA-PK is an enzyme that is required for proper DNA-repair and is thought to confer radio-
resistance in cancer cells. As a consequence, it is a high-profile validated target for new
pharmaceutical development. However, no FDA-approved DNA-PK inhibitors have
emerged, despite many years of drug discovery and lead optimization. This is largely
because existing DNA-PK inhibitors suffer from poor pharmacokinetics. They are not well
absorbed and/or are unstable, with a short plasma half-life. Here, we identified the first FDA …
resistance in cancer cells. As a consequence, it is a high-profile validated target for new
pharmaceutical development. However, no FDA-approved DNA-PK inhibitors have
emerged, despite many years of drug discovery and lead optimization. This is largely
because existing DNA-PK inhibitors suffer from poor pharmacokinetics. They are not well
absorbed and/or are unstable, with a short plasma half-life. Here, we identified the first FDA …
以上显示的是最相近的搜索结果。 查看全部搜索结果